Sunshine State Sounds Alarm: Florida Lawmakers Push FDA To Combat Flood Of Fake Obesity Meds

Florida Members of Congress Sound Alarm on Surge of Counterfeit Weight Loss Drugs, Urge FDA Action

A bipartisan group of U.S. lawmakers, including several prominent members from Florida, has sent a pointed letter to FDA Commissioner Marty Makary, urging swift and decisive action to combat the dangerous surge of illegal and counterfeit anti-obesity medications (AOMs), such as semaglutide and tirzepatide, flooding into the United States from unregistered foreign sources.

The July 25 letter, led by Representatives Richard Hudson and Herbert C. Conaway, Jr., and co-signed by dozens of others including Florida’s own Dr. Neal Dunn, Vern Buchanan, Gus Bilirakis, Kat Cammack, Greg Steube, Laurel Lee, Scott Fitzgerald and Aaron Bean, highlights mounting concerns over patient safety—particularly in states like Florida, where demand for weight loss drugs is high.

“We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications… Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences,” lawmakers wrote.

Recent warnings from the FBI and the National Association of Attorneys General have underscored the gravity of the situation. Authorities have found that many counterfeit products, often disguised as legitimate treatments like Ozempic and Wegovy (both containing semaglutide), are actually laced with unknown drugs, harmful impurities, or contain no real active ingredient at all. In some cases, shipments from China, Turkey, and India have entered the U.S.—including Florida—hidden among packages labeled as tea, dog food, or even t-shirts.

According to the lawmakers, the FDA’s own import database records 239 shipments of GLP-1 active ingredients from unregistered suppliers, most notably Chinese firms that have never undergone FDA inspection and are prohibited from selling such medications domestically in China. The letter calls on the FDA to use its full enforcement authority to block these shipments at the border, issue import alerts, and ramp up oversight of noncompliant online sellers targeting Floridians and other Americans.

Health professionals in Florida echo these concerns. With obesity rates on the rise and the state’s sizable elderly population especially vulnerable, the stakes could not be higher. Counterfeit drugs often contain dangerously high dosages or toxic impurities. When Floridians self-inject these substances—sometimes using unsterile equipment and improper techniques—the risk of infection, overdose, and fatal errors increases dramatically.

The lawmakers stress that while legitimate compounded drugs made in licensed pharmacies have a vital place, the influx of illegal, unapproved AOMs marketed online and through other channels poses “a significant threat to consumer health, including the potential for adverse reactions, toxic exposure, or overdose.”

The congressional letter urges the FDA to coordinate with U.S. Customs and Border Protection for immediate action. Among the chief demands: strict border enforcement against illicit shipments, more aggressive monitoring of online sellers in states like Florida, and prompt civil or criminal actions against violators.

With the deadline for the FDA’s response set for July 30, Florida residents—and lawmakers—are watching closely, concerned that without urgent intervention, the Sunshine State may remain a target for dangerous counterfeit weight loss medications.

MORE ARTICLES - TAMPA FREE PRESS

 

TAMPA FREE PRESS

Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.

Android Users: Download our free app to stay up-to-date on the latest news.

Connect with us: Follow the Tampa Free Press on Facebook and Twitter for breaking news and updates.

Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox.